- Elite Trade Club
- Posts
- Telehealth Platform Operator Climbs 41%
Telehealth Platform Operator Climbs 41%
Adam Garcia
April 29, 2025
Good Afternoon!
Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.
Energy Sector Watch (Sponsored)
On Behalf of Azincourt Energy Corp
Uranium has doubled since 2020.
Saskatchewan’s uranium sales just hit $2.6 billion, up 62% year-over-year.
Cameco says the long-term outlook has never been stronger.
Now layer on the global demand curve:
30+ countries pledging to triple nuclear capacity
AI data centers expected to use 12% of US electricity by 2028
Germany reversing course and returning to nuclear
The setup is here.
And one company has plans to drill in the heart of it all: Canada’s Athabasca Basin.
With early uranium hits, expanding alteration zones, and proximity to NexGen and Cameco, this could be the next name to watch in the sector.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
Markets 📈
U.S. stock indices closed slightly higher on Tuesday, supported by declining Treasury yields. Meanwhile, investors continued to assess more Q1 earnings reports and digested Secretary Bessent’s comments, saying that many countries had come up with very good tariff proposals to the U.S.
|
|
Market-Moving News 📈
Pharmaceuticals
Merck Stakes $1B on Delaware Plant to Bring Keytruda Home
Merck (NYSE: MRK) will invest $1 billion to construct a 470,000-square-foot factory in Wilmington, Delaware, to manufacture its cancer drug Keytruda in the U.S. for the first time. The project is expected to be completed in 2028, creating over 500 permanent jobs and thousands of construction jobs.
This step shields Keytruda from tariffs on drug ingredients shipped from abroad. Making the drug in the U.S. keeps costs steady and ensures patients get it on time. The factory may also earn government funding to create jobs in the U.S.
Keytruda’s patent will expire later this decade, so producing it now protects Merck’s profits. Merck is moving quickly to stay ahead of other drug companies that are facing similar tariff issues.
Other companies that are slower to build U.S. factories may face higher costs. Since the tax changes, Merck has already invested $12 billion in U.S. manufacturing, demonstrating its trust in local production over foreign factories.
Investors should note that this $1 billion investment will raise costs now but save money later by avoiding tariffs and securing government support.
With Keytruda’s patent ending soon, a U.S. factory keeps profits strong, protecting investor returns. If trade problems grow, Merck’s U.S. focus reduces risks and supports steady earnings.
Future of Global Energy (Sponsored)
On Behalf of Azincourt Energy Corp
When Peter Thiel joins the board of a uranium enrichment startup and backs a $50 million raise, you pay attention.
Because this isn’t just Thiel.
It’s Gates with TerraPower. Bezos with General Fusion. Altman with Oklo. And now Thiel with General Matter.
The smartest minds of this generation are placing billion-dollar bets on one thing: Nuclear.
And it’s not hard to see why.
Global electricity demand is set to soar 50% by 2050.
AI. Data centers. EVs. Every megatrend needs power — and clean, baseload nuclear is the only source that scales.
Meanwhile, uranium production can’t keep up.
That’s why a tiny uranium explorer in the Athabasca Basin — home to the world’s highest-grade deposits — may soon be on every investor's radar.
Drill programs are planned. Momentum is building. And the market hasn’t caught up.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
Logistics
UPS Slashes 20,000 Jobs, Shutters 73 Sites in Bid to Boost Profitability
UPS (NYSE: UPS) will eliminate 20,000 jobs and close 73 U.S. facilities by mid-year as part of a network overhaul. This follows a deal to reduce Amazon's parcel volume by more than half by 2026. As the company continues its review, more sites could face closure.
The layoffs will affect both union and non-union workers. With approximately 490,000 employees globally, UPS has not specified which locations will be affected.
While quarterly revenue reached $21.6 billion, beating Wall Street’s expectations, the company kept its yearly guidance unchanged due to economic uncertainty. We see this as UPS waiting to confirm savings before making bold promises.
Operations will shift to newer, automated hubs that handle packages faster with fewer workers. Closures involve both leased and owned buildings. UPS sees rising wages and softer consumer demand, making this the right time to streamline. Existing labor contracts remain in place, with no new union talks tied to the announcement.
As closures wrap up and Amazon volume shrinks through 2026, UPS will share savings targets. A leaner network could reduce reliance on any single customer and better weather economic ups and downs.
Honest News (Sponsored)
Check out 1440--the fastest way to an impartial point-of-view.
The team at 1440 scours over 100+ sources ranging from culture and science to sports and politics to create one email that gets you all caught up on the day’s events in 5 minutes.
According to Gallup, 51% of Americans can’t think of a news source that reports the news objectively.
It’s 100% free. It has everything you need to be aware of for the day. And most importantly, it simplifies your life.
Automotive
Engine Wear Risk Forces GM to Inspect Nearly 600 K Full-Size Models
General Motors (NYSE: GM) is recalling about 598,000 Cadillac, Chevrolet, and GMC pickups and SUVs from the 2021–24 model years due to issues with the 6.2-liter V-8 engine. Starting in early June, owners will receive letters to have dealers inspect and, if necessary, replace the engines at no cost.
Two problems are at play: sediment damaging bearings and crankshafts made incorrectly. Either can cause engines to fail suddenly. Vehicles that pass inspection will use heavier oil and get new service labels. No injuries have been reported.
Trending now: Real-time alerts. Live charts. Expert insights. All in one app—get Stocks.News today (ad)
The National Highway Traffic Safety Administration began investigating after reports of stalls surged in January. Data show engines cutting out during driving. GM is stockpiling parts to avoid delays, especially with summer travel approaching. While fixing this issue now costs money, it protects GM’s reputation with truck and SUV buyers.
Owners can check their vehicle's identification number at a dealer or on NHTSA’s recall portal to determine if their car is affected, rather than waiting for letters.
This recall targets popular models, and General Motors is quickly addressing the issue. By tackling this head-on, the company aims to maintain customer trust and prevent owners from switching to competitors.
Top Winners and Losers 🔥
Lifemd Inc [LFMD] $8.62 (+41.31%)
LifeMD stock jumped after announcing plans to offer cheaper access to Wegovy, a weight-loss drug, through NovoCare Pharmacy and expanding into the women’s health market via a strategic acquisition.
Leggett & Platt Inc [LEG] $9.57 (+31.67%)
Leggett & Platt rose today after posting better-than-expected Q1 earnings despite reporting lower year-on-year revenues.
Hims & Hers Health Inc [HIMS] $35.09 (+23.21%)
Hims & Hers surged after Novo Nordisk partnered with the company to distribute its Wegovy drug through HIMS’ telehealth platform.
NeoGenomics Inc [NEO] $6.58 (-34.00%)
NeoGenomics fell on Tuesday after missing Q1 revenue estimates, despite raising full-year guidance and announcing a partnership with Ultima Genomics Inc.
Brinker International [EAT] $137.14 (-14.68%)
Brinker tumbled despite beating Q3 estimates, as investors reacted to a weak Q4 earnings outlook amid slowing consumer spending.
Kforce Inc [KFRC] $36.69 (-14.20%)
Kforce declined due to weaker-than-expected Q1 results and a continued year-over-year revenue decline.
Uranium Supply Crunch (Sponsored)
On Behalf of Azincourt Energy Corp
Right now, the US has 94 nuclear reactors.
And 90% of the fuel they run on? It’s imported.
Tariffs are coming. Tensions are rising. And the government knows it needs more domestic-friendly supply.
Why Peter Thiel just joined the board of a uranium enrichment startup. Why Canada’s uranium is now more strategic than ever.
And why one tiny explorer in Saskatchewan’s Athabasca Basin could be positioned perfectly. The company has two active projects.
It’s drilling in the richest uranium district on Earth.
And as the US tries to secure its nuclear future, Canadian explorers like this one may be the first call utilities make.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
*Standard message/carrier rates may apply.
Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.
